top of page


Key references for the Trocept platform

Please contact us for any further information




       Most relevant papers

  1. Uusi-Kerttula, H., et al., Ad5(NULL)-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies. Clin Cancer Res, 2018. 24(17): p. 4215-4224. 

  2. Davies, J.A., et al., Efficient Intravenous Tumor Targeting Using the αvβ6 Integrin-Selective Precision Virotherapy Ad5(NULL)-A20. Viruses, 2021. 13(5). 

  3. Cole D, Khanolkar R, Davies J, et al
    1349 TROCEPT mediated in-tumor delivery of immune checkpoint inhibitors reduces systemic toxicity risks and boosts immune activation. Journal for ImmunoTherapy of Cancer 2022;10

    Related papers

  4. Waddington, S.N., et al., Adenovirus serotype 5 hexon mediates liver gene transfer. Cell, 2008. 132(3): p. 397-409.  

  5. Parker, A.L., et al., Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood, 2006. 108(8): p. 2554-61. 

  6. Alba, R., et al., Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood, 2009. 114(5): p. 965-71.

  7. Alba, R., et al., Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood, 2010. 116(15): p. 2656-64.

  8. Parker, A.L., et al., Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. J Virol, 2009. 83(1): p. 479-83.

  9. Parker, A.L., et al., Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. J Virol, 2007. 81(7): p. 3627-31

  10. Waddington, S.N., et al., Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. J Virol, 2007. 81(17): p. 9568-71.

  11. Uusi-Kerttula, H., et al., Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies. Hum Gene Ther, 2015. 26(5): p. 320-9. 

  12. Uusi-Kerttula, H., et al., Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget, 2016. 7(19): p. 27926-37. 

    Relevant reviews and commentaries

  13. Cunliffe, T.G., E.A. Bates, and A.L. Parker, Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies. Cancers (Basel), 2020. 12(11). 

  14. Teijeira Crespo, A., et al., Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity. Immunology, 2021. 163(4): p. 389-398. 

  15. Uusi-Kerttula, H., et al., Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications. Viruses, 2015. 7(11): p. 6009-42. 

  16. Uusi-Kerttula, H. and A.L. Parker, Precision virotherapies: Coming soon. Oncotarget, 2018. 9(86): p. 35605-35606.

  17. Coughlan, L., et al., Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses, 2010. 2(10): p. 2290-355.

bottom of page